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ABSTRACT 
We studied the impact of FK506, a potent immunosuppressant, 
on graft coronary disease and graft infiltrating lymphocyte 
subset following rat heart transplantation. Fisher heart grafts 
transplanted into Lewis recipients were divided into 3 groups: 
Control (n=7), treated with FK506 at a dose of 0.32mg/kg/day 
i.m.(n=7),treated with Cyclosporine A at a dose of 10mg/kg/day 
i. m. (n=7). Grafts were removed on the 71st day in the treated 
groups and on rejection in the control. We blindly scored graft 
rejection and graft coronary disease on a scale of 0-4. Graft 
infiltrating lymphocytes were investigated by flowcytometric 
analysis using the following monoclonal antibodies: W3/25; 
anti-helper T lymphocyte, OX8; anti-suppressor & cytotoxic T 
lymphocyte and OX39; anti-interleukin 2 receptor. There was no 
difference of graft rejection between two treated groups (FK506 
1.66+0.49 vs Cyclosporine 1.45+0.37), but FK506 group expressed 
severe graft coronary disease (FK506 2 .14+0. 82 vs Cyclosporine 
0. 78+0. 17 p<O. 01) in this model. In flowcytometric analysis, we 
found an increased proportion of OX8-positive lymphocytes (FK506 
25.7+6.4% vs Cyclosporine 4.9+2.4% p<O.Ol). These results suggest 
that suppressor of cytotoxic T lymphocytes may be involved in 
graft coronary disease. 
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FK506 is a macrolide antibiotic, which has strong immunosup-
pressive potential. The immunosuppressive mechanism of FK506 is 
known to suppress the synthesis of interleukin 2 and the activa-
tion of helper T lymphocyte, similar to Cyclosporine A. 1-3 
Also FK506 may induce donor-specific suppressor T lymphocyte in 
rat heart transplantation. Ochiai et al reported FK506 can 
. d 4 1n uce graft tolerance. Thus FK506 is expected to be applied 
in the near future. 
In long term follow up of orthotopic heart transplant pa-
tients, new problem of rapidly progressive graft coronary dis-
ease (GCD) became apparent. The pathogenesis of GCD remains 
unknown. But GCD is supposed to be a form of immunological 
reaction in the chronic phase of heart transplantation. 
We investigated the impact of FK506 on graft coronary dis-
ease compared with Cyclosporine A and the process of GCD using 
flowcytometric analysis of lymphocyte-surface markers. 
MATERIALS AND METHODS 
Transplantation 
For this study, two different strains of male inbred rats 
were selected, Lewis (LEW)(RT1 1 ) as recipients and Fisher 
(F344) (RT1 1 vl) as donors. They were purchased from Charles-River 
Japan Co.(Atugi,Japan) All animals received humane care in com-
pliance with the "Principles of Laboratory Animal care" formulat-
ed by the National Society for Medical Research and the "Guide 
for the Care and Use of Laboratory Animals" prepared by the 
National Academy of Science and published by National Institutes 
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of Health(NIH Publication No. 86-23 revised 1985). 
Heterotopic intraabdominal heart transplantation was per-
formed as Ono and Lindsay described. 5 Fisher rat was first 
anesthetized by inhalation of ether. After median laparotomy, 
the donor rat was heparinized at a dose of 1mg/kg from inferior 
vena cava. Anterior thoracotomy was followed by a bolus injec-
tion of St.Thomas cardioplegic solution from inferior vena cava. 
Afterward cardioplegia was injected from descending aorta and 
cardiac arrest was accomplished. Procurement of the graft heart 
was completed by division of ascending aorta and pulmonary 
artery and ligation-division of the venae cavae & left atrium. 
The graft heart was immersed in cold saline. Recipient Lewis rat 
was anesthetized by ether inhalation. The median laparotomy was 
performed and abdominal aorta and inferior vena cava were dis-
sected freely beneath their renal branches. Abdominal aorta & 
inferior vena cava were cross-clamped independently. Aortoaortic 
end-to-side anastomosis and pulmonocaval end-to-side anastomosis 
were performed by 8-0 Prolene continuous sutures. Mean ischemic 
period was approximately 60 minutes. 
Transplanted rats were divided into 3 groups as follows: 
control without immunosuppression (n=7), treated with cyclospo-
rine A at a dose of 10mg/kg/day i. m. (n=7). and treated with 
FK506 at a dose of 0.32mg/kg/day i.m.(n=7). The immunosuppres-
sants were injected intramuscularly in alternate legs daily for 
70 days. Pulsation of the graft was confirmed by daily palpation 
and the cessation of pulsation was diagnosed as graft rejection. 
All grafts of control group were rejected and mean graft 
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survival was 10. 3 days. Grafts were removed on the day of the 
reject i on. Grafts of the immunosuppressed groups achieved long-
term surv i val more than 70 days and sacrificed by terminal ether 
anesthesia on the 71st day . The removed grafts were evaluated for 
graft re j ection, graft coronary disease and surface markers 
lymphocytes by the following methods. 
Histological Examination 
of 
The basal half of the graft heart was fixed by formaldehyde 
for microscopic examination. Graft rejection was graded accord-
ing to International Society for Heart Transplantation(ISHT) 
standardized Grading System by the Hematoxylin-Eosin stained 
specimen.6 Graft coronary disease was graded by the Elastica van 
Gieson stained specimen as follows; grade 0: no stenosis, 1: 1 -
25% stenosis, 2: 25-50%, 3:50-75%, 4:75-100%. Both evaluations 
were carried out blindl y . 
Flowcytometric Analysis 
Lymphocytic surface marker analysis by flowcytometry, using 
EPICS model 753: Coulter Electronic Co.(Hialeah,Florida U.S.A), 
was performed on both peripheral blood lymphocytes(PBL) and graft 
infiltrating lymphocytes(GIL). 
PBL Preparation: PBL were prepared from heparinized blood using 
Lympholyte-R:Cederlane Lab.( Hornby,ON, Canada). Blood was over-
laid on Lympholyte-R and centrifuged at 2200 r.p.m. for 30 
minutes in room temperature. The layer of lymphocytes was care-
fully aspirated. Lymphocytes were suspended in RPMI 1640 culture 
medium containing 1% of fetal calf serum and 1% of 0.1% NaN 2 . 
GIL Preparation: The apical half of the graft heart was minced 
by a tissue homogenizer and cells were released according to 
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Totterman et al described . 7 The tissue homogenate was incubated 
with 3ml of digestion medium (20mM Hepes Buffer f rom Sigma, 136mM 
NaCl, 4.7mM KCl, 0.65mM MgS04 , and 1.2mM CaCl 2 , pH 7.45 ) contain-
ing collagenase 2mg/ml, DNAse 0.05mg/ml and 1.5% bov i ne s e r um 
albumin. After agitation and incubation at 37 C for 1 hour, ce ll s 
were filtrated through nylon mesh ( 100)l m) to remove aggregates 
and overlaid on Lympholyte-R. Thereafter centrifugion at 2200 
r. p.m. for 30 minutes made a clear lymphocytic layer and these 
cells were carefully aspirated and suspended in the same medium 
as PBL. 
Antibody Incubation: The lymphocyte suspensions of the GIL and 
PBL were incubated with the optimal concentration of monoclonal 
antibodies at 4 C for 30 minutes in a dark incubat i on chamber. 
Lymphocyte-surface markers examined were W3/25 : anti - helper T 
lymphocyte antibody labeled with fluorescein(FITC), OX8: anti -
suppressor & cytotoxic T lymphocyte antibody labeled with phyco-
erythrin(PE), OX39: anti-interleukin 2 receptor antibody labeled 
with PE. Two combinations of the antibodies, W3/25 with OX8 and 
W3/25 with OX39, were stained doubly and used for two color 
flowcytometry analysis. The cells were gated optimally by forward 
scatter (cell size) and lateral scatter (granularity) for lympho-
cyte. Appropriate filters, 560nm short pass filter for FITC and 
590nm long pass filter for PE, were used in the analysis. 
All of the statistical analysis was performed using the 
ANOVA test. 
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Results 
Graft rejection of the control group was severe, compatible 
with ISHT grade 4. FK506 group and Cyclosporine A group showed 
mild to moderate rejection respectively and their grading did 
not differ significantly (Figure 1). 
In respect of graft coronary disease, the control group was 
almost free of coronary stenotic lesions. Both FK506 and Cyclos-
porine A caused GCD and their subquantitative evaluation re-
vealed significant difference between the two groups. FK506 
group showed more severe GCD than seen in Cyclosporine A treated 
grafts (Figure 2). 
The flowcytometric analysis of the lymphocytic surface 
markers showed an interesting difference between the three 
groups in terms of graft infiltrating lymphocytes. 
First the proportion of W3/25 positive cells in the GIL, the 
helper T lymphocyte subpopulation, in the FK506 group was sig-
nificantly greater than in the control group and significantly 
lower than Cyclosporine A group. (Figure 4) 
The oxa positive cell proportion in the GIL, the cytotoxic 
and suppressor T lymphocyte subpopulations, in the FK506 group 
was significantly lower than the control group but greater than 
the Cyclosporine A group (Figure 5). 
OX39, which binds to the interleukin 2 receptor of activated 
lymphocytes showed no statistically significant difference among 
the three groups in the GIL evaluation (Figure 6). 
These data suggest that the non-treated rejector had the 
most intense CD8 lymphocytic infiltrate among the three groups 
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and that the FK506 treated graft had a different GIL population 
than the Cyclosporine A treated grafts. 
In the flowcytometric analysis of the peripheral blood 
lymphocytes, none of these markers were significantly different 
among the three groups. 
DISCUSSION 
FK506 has been reported to prolong allograft survival in 
different species of animals. Rat heart allograft survival was 
reportedly achieved by a short course of treatment in the acute 
· w1'thout any serious adverse effect. 8- 10 phase of reject1on 
But there were few reports on chronic administration of FK506 in 
rat heart transplantation. Our report focuses on how maintenance 
use of FK506 affects rat heart allograft, especially in terms of 
graft coronary disease. In clinical heart transplantation, graft 
coronary disease has turned out to be an important factor in 
determining transplant outcome. Narrod et al reported an inc i-
dence of 66% of graft coronary disease 6 years after heart trans-
plantation, but its pathogenesis remains unknown. 11- 14 If FK506 
will be applied into clinical heart transplantation, its impact 
on graft coronary disease must be carefully evaluated. 
our experiment revealed FK506 at a dose of 0. 32mg/kg/day 
i .m., 
more 
which may be a relatively high dose, was associated with 
progressive graft coronary disease than Cyclosporine A. 
Vascular inflammatory changes were reported in canine renal 
transplantation treated with FK506. 15 But there have been no 
reports of vascular changes in the rat with administration of 
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FK50616-17 and we have not observed any vascular changes in the 
native heart, lung kidney and aorta of both recipients and rats 
without allografting receiving 0.32 mg/kg/day i.m. daily for 70 
days. And Meiser et al. also reported FK506 caused severe graft 
l 18 So it is coronary disease in rat allotransplantation mode . 
appropriate to consider the coronary stenotic lesions observed in 
our experiment to be the expression of graft coronary disease and 
not a partial expression of the generalized vascular adverse 
effect of FK506. 
Flowcytometric analysis of surface markers on the graft 
infiltrating lymphocytes reflects the rejection process more 
accurately than the same analysis on peripheral blood lymphocytes 
and quantitatively. Our method of the preparation for graft 
infiltrating lymphocytes was highly efficient and specific, and 
thus the results were reproducible and excellent for immunologi-
cal analysis of the intragraft event. So we expect our methods 
can be useful for diagnosis of rejection in the clinical prac-
tice. In this study we examined the T lymphocyte subsets, which 
infiltrated grafts under chronic FK506 and cyclosporine immuno-
suppression. We found the suppressor and cytotoxic T(CD8) lympho-
cyte proportion of the FK506 group to be increased significantly 
compared with the Cyclosporine A group. Woo et al reported reduc-
tion of W3/25: OX8 ratio in splenic lymphocytes in rat stimulated 
These by sheep erythrocytes treated by FK506 and Cyclosporine A. 
observations and our results show that FK506 has an OX8 positive 
cell induction effect. 19- 21 
Rejection grade of the two groups were not different and 
interestingly the graft coronary disease of the FK506 group was 
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more advanced than in the Cyclosporine A group. These results 
lead us to the idea that the cytotoxic or suppressor T lymphocyte 
was involved in the graft coronary disease. Macrophages and 
smooth muscle cells were known to exist in lesions of graft 
coronary disease. 22 But immunoreaction of these cells was not 
alloantigen-specific and these cells exist in the atherosclerotic 
lesions, therefore expression of macrophages and endothelial 
proliferation may only be the terminal result of endothelial 
injury. Therefore, we speculate that cytotoxic T lymphocytes play 
a role in initiation and proliferation by recognizing and de-
stroying graft vascular endothelium, which thus results in graft 
coronary disease. And we have to evaluate further,the localiza-
tion of the antigens, multiple doses studies, the adoptive graft 
coronary disease model and clinical evaluation of CDS antigen in 
biopsy specimens and their correlation with graft coronary dis-
ease, to prove this hypothesis. 
FK506 is one of the most potent immunosuppressants that can 
be applied in clinical transplantation. However we have observed 
its possible adverse impact on graft coronary disease with this 
et al. experimental model with rat heart transplant. Armitage 
reported that there has been no realization of vasculitis in 
clinical experience with FK506 in heart transplantation with 
median follow-up period of 110 days. 23 And Flavin et al. reported 
that cynomolgus monkeys treated with FK506 following heterotopic 
heart transplantation expressed only a limited incidence of graft 
coronary disease and also their lesions may be different from the 
24 d" lesions among the rat allografts. So the graft coronary 1sease 
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observed in this study may be a unique to the rat heart trans-
plantation model. But we have to carefully examine the impact of 
FK506 on graft coronary disease in clinical practice and experi-
mental model. 
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Figure 1 Graft Rejection 
Rejection grade of CsA and FK506 did not differ significant-
ly. 
CsA: Cyclosporine A NS: No Significance 
Figure 2 
Graft 
Graft Coronary Disease 
coronary disease of FK506 was 
Cyclosporine A. 
CsA: Cyclosporine A 
Grading Scale of Graft Coronary Disease; 
more advanced than 
Grade 0: no stenosis, 1: 1-25% stenosis, 2: 25-50%, 
3: 50-75%, 4: 75-100% 
Figure 3 Graft Coronary Disease Lesion ( X 400 ) 
Left picture shows the epicardial lesion of FK506 and right 
one shows the epicardial lesion of Cyclosporine A. FK506 
group expressed more stenotic lesions. 
Figure 4 Flowcytometric Analysis 
Proportion of W3/25 positive lymphocytes ( Th ) among graft 
infiltrating lymphocytes. 
Figure 5 Flowcytometric Analysis 
Proportion of OX8 positive lymphocytes ( Ts/c ) among graft 
infiltrating lymphocytes. 
Figure 6 Flowcytometric Analysis 
Proportion of OX39 ( IL2R ) positive lymphocytes among graft 
infiltrating lymphocytes. 
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TABLE 1 Grading of graft rejection and graft coronary disease 
Group Dose 
Control (n=7) no treatment 
FK506 (n=7) 0.32mg/kg/day i.m. 
CsA (n=7) 10mg/kg/day i.m. 
GR 
4.00±0.00 
1.66±0.49* 
1.45±0.37* 
GCD 
0.13±0.35 
2.14±0.82** 
0.78±0.17 
GR : graft rejection 
CsA : Cyclosporine A 
GCD graft coronary disease 
GCD grading ; grade 0: no stenosis, 1: 1-25% stenosis, 2 25-50% 
3 : 50-75%, 4 :75-100% 
Figures stand for mean ± standard deviation 
*:p<0.01 vs control **:p<0.01 vs both control and CsA 
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TABLE 2 Flowcytometric analysis of graft infiltrating lymphocytes 
Proportion of surface marker positive cells (%) 
Group 
Control 
FK506 
CsA 
W3/25 (Th) 
49.8±19.1 
70.5±5.6* 
86.9±2.8** 
CsA: Cyclosporine A 
OX8 (Ts/c) 
43.3±20.3 
25.7±6.4* 
4.9±2.4** 
OX39 (IL2R) 
52.1±14.3 
48.4±14.4 
51.7±21.3 
Figures stand for mean ± standard deviation 
* :p<0.01 vs Cyclosporine A and p<0.05 vs control 
**:p<0.01 vs control 
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TABLE 3 Flowcytometric analysis of peripheral blood lymphocytes 
Proportion of surface marker positive cell (%) 
Group 
Control 
FK506 
CsA 
W3/25 (Th) 
62.2±8.0 
68.1±10.5 
73.0±9.4 
CsA : Cyclosporine A 
OXB (Ts/c) 
25.7±3.4 
22.8±1.2 
23.2±8.5 
OX39 (IL2R) 
26.2±11.0 
34.6±14.0 
28.0±14.4 
Figures stand for mean± standard deviation 
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